REPAIR AND REGENERATION OF OCULAR TISSUE USING POSTPARTUM-DERIVED CELLS

• US 20100272803A1
• Filed: 03/25/2008
• Published: 10/28/2010
• Est. Priority Date: 06/27/2003
• Status: Active Grant

• Current Assignee: Depuy Synthes Products Incorporated (Johnson & Johnson)
• Original Assignee: Depuy Synthes Products Incorporated (Johnson & Johnson)
• Inventors: Messina, Darin, Mistry, Sanjay
• Granted Patent: US 8,790,637 B2
• Time in Patent Office: Days
• US Class Current: 424/484
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/51 Umbilical cord; Umbilical cord blood; Umbilical stem cells
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: C12N 2500/32 Amino acids
• CPC Class Codes: C12N 2500/34 Sugars
• CPC Class Codes: C12N 2500/44 Thiols, e.g. mercaptoethanol
• CPC Class Codes: C12N 2500/90 Serum-free medium, which may still contain naturally-sourced components
• CPC Class Codes: C12N 2500/95 Protein-free medium and culture conditions
• CPC Class Codes: C12N 2501/12 Hepatocyte growth factor [HGF]
• CPC Class Codes: C12N 2501/21 Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
• CPC Class Codes: C12N 2501/23 Interleukins [IL]
• CPC Class Codes: C12N 2502/02 embryonic cells
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 2506/025 from extra-embryonic cells, e.g. trophoblast, placenta
• CPC Class Codes: C12N 2506/03 from non-embryonic pluripotent stem cells
• CPC Class Codes: C12N 2506/08 from cells of the nervous system
• CPC Class Codes: C12N 2509/00 Methods for the dissociation of cells, e.g. specific use of enzymes
• CPC Class Codes: C12N 2533/50 Proteins
• CPC Class Codes: C12N 5/0605 : Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
• CPC Class Codes: C12N 5/0607 : Non-embryonic pluripotent stem cells, e.g. MASC induced pluripotent stem cells C12N5/0696
• CPC Class Codes: C12N 5/0618 : Cells of the nervous system

Abstract

Cells derived from postpartum umbilicus and placenta are disclosed. Pharmaceutical compositions, devices and methods for the regeneration or repair of ocular tissue using the postpartum-derived cells are also disclosed.

Claims

1. A method for treating a patient having a retinopathy or a retinal/macular disorder, the method comprising administering to the patient'"'"'s eye umbilicus-derived cells, in an amount effective to treat the retinopathy or a retinal/macular disorder, wherein the cells are capable of self-renewal and expansion in culture, have the potential to differentiate into cells of at least a neural phenotype, and have the following characteristics:

a. Potential for at least 40 population doublings in culture;

b. Attachment and expansion on a coated or uncoated tissue culture vessel, wherein the coated tissue culture vessel comprises a coating of gelatin, laminin, collagen, polyornithine, vitronectin, or fibronectin;

c. Production of vimentin and alpha-smooth muscle actin;

d. Production of CD10, CD13, CD44, CD73, and CD90; and

e. Expression of a gene, which is relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an ileac crest bone marrow cell, is increased for a gene encoding interleukin 8 and reticulon 1.

2. The method of claim 1, wherein the umbilicus-derived cells are positive for HLA-A, B, C, and negative for CD31, CD34, CD45, CD117, and CD141.

3. The method of claim 1, wherein the umbilicus-derived cells are expanded in culture prior to administering to the patient'"'"'s eye.

4. The method of claim 1, wherein the retinopathy or a retinal/macular disorder is age-related macular degeneration.

5. The method of claim 1, wherein the retinopathy or a retinal/macular disorder is glaucoma.

6. The method of claim 1, wherein the umbilicus-derived cells are administered with at least one other agent.

7. The method of claim 6, wherein the at least one other agent is administered simultaneously with, or before, or after, the umbilicus-derived cells.

8. The method of claim 1, wherein the umbilicus-derived cells are administered to the interior of the patient'"'"'s eye.

9. The method of claim 8, wherein the umbilicus-derived cells are administered through a cannula or from a device inserted in the patient'"'"'s eye.

10. The method of claim 8, wherein the umbilicus-derived cells are administered by the insertion of a matrix or scaffold containing the cells.

11. A method for preventing the loss of photoreceptor cells associated with a retinopathy or a retinal/macular disorder in a patient, the method comprising administering to the patient'"'"'s eye umbilicus-derived cells, in an amount effective to prevent the loss of photoreceptor cells, wherein the cells are capable of self-renewal and expansion in culture, have the potential to differentiate into cells of at least a neural phenotype, and have the following characteristics:

a. Potential for at least 40 population doublings in culture;

b. Attachment and expansion on a coated or uncoated tissue culture vessel, wherein the coated tissue culture vessel comprises a coating of gelatin, laminin, collagen, polyornithine, vitronectin, or fibronectin;

c. Production of vimentin and alpha-smooth muscle actin;

d. Production of CD10, CD13, CD44, CD73, and CD90; and

e. Expression of a gene, which is relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an ileac crest bone marrow cell, is increased for a gene encoding interleukin 8 and reticulon 1.

12. The method of claim 11, wherein the umbilicus-derived cells are positive for HLA-A, B, C, and negative for CD31, CD34, CD45, CD117, and CD141.

13. The method of claim 11, wherein the umbilicus-derived cells are expanded in culture prior to administering to the patient'"'"'s eye.

14. The method of claim 11, wherein the retinopathy or a retinal/macular disorder is age-related macular degeneration.

15. The method of claim 11, wherein the retinopathy or a retinal/macular disorder is glaucoma.

16. The method of claim 11, wherein the loss of photoreceptor cells is prevented by inhibiting the apoptosis of the photoreceptor cells.

17. The method of claim 11, wherein the loss of photoreceptor cells is prevented by stimulating the phagocytosis of shed photoreceptor fragments.

18. The method of claim 17, wherein the umbilicus-derived cells phagocytose the shed photoreceptor fragments.

19. The method of claim 17, wherein the umbilicus-derived cells stimulate the phagocytosis of shed photoreceptor fragments by RPE cells.

20. The method of claim 11, wherein the loss of photoreceptor cells is prevented by replacing the photoreceptor cells.

21. The method of claim 20, wherein the photoreceptor cells are replaced by the umbilicus-derived cells differentiating retinal progenitor cells into photoreceptor cells.

22. The method of claim 11, wherein the loss of photoreceptor cells is prevented by re-surfacing Bruch'"'"'s membrane.

23. The method of claim 11, wherein the cells are administered with at least one other agent.

24. The method of claim 23, wherein the at least one other agent is administered simultaneously with, or before, or after, the cells.

25. The method of claim 11, wherein the cells are administered to the interior of the patient'"'"'s eye.

26. The method of claim 25, wherein the cells are administered through a cannula or from a device inserted in the patient'"'"'s eye.

27. The method of claim 25, wherein the cells are administered by the insertion of a matrix or scaffold containing the cells.